EMA Application withdrawn: Contusugene Ladenovec Gendux — Gendux Molecular Limited

View source ↗

Summary

The EMA withdrawal of the application for Contusugene Ladenovec Gendux by Gendux Molecular Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Squamous Cell
• Head and Neck Neoplasms

Drugs mentioned

• Contusugene Ladenovec Gendux

Snippet

Status: Application withdrawn. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Squamous Cell. MAH: Gendux Molecular Limited. Decision date: 31/12/2009